TY - JOUR
AR - GCCR-2020-1-105
TI - Immune Checkpoint Myocarditis from Adjuvant Treatment of Melanoma
AU - John , Dasher
AU - Lavanya , Kondapalli
AU - Carrie, Lenneman
JO - Global Clinical Case Reports
PY - 2020
DA - Thu 31, Dec 2020
SN - 
DO - http://dx.doi.org/10.31487/j.GCCR.2020.01.05
UR - https://www.sciencerepository.org/immune-checkpoint-myocarditis-from-adjuvant-treatment-of-melanoma_GCCR-2020-1-105 
KW - Immunotherapy, myocarditis, immune-related adverse events, cardiotoxicity
AB - Immune checkpoint inhibitors (ICIs) are effective therapy for many metastatic cancers and are now being
used as adjuvant treatment for many stage III cancers to reduce the high risk of reoccurrence. ICIs activate
a patient’s own T-cells to fight cancer, but in some cases, immune-related adverse events (irAEs) with
inflammation of many organs can occur. Rare cases of myocarditis have been reported. More data is needed
to improve our ability to monitor, diagnose and treat irAEs.